Globus Medical (GMED) Gets a Hold Rating from Oppenheimer


In a report released yesterday, Steven Lichtman from Oppenheimer maintained a Hold rating on Globus Medical (GMED). The company’s shares closed yesterday at $47.79.

According to TipRanks.com, Lichtman ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.1% and a 49.5% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tandem Diabetes Care Inc, and Boston Scientific Corp.

Currently, the analyst consensus on Globus Medical is a Moderate Buy with an average price target of $55.40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $57.83 and a one-year low of $38.01. Currently, Globus Medical has an average volume of 718.4K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Anthony L. Williams, the President of GMED sold 212,082 shares for a total of $9,931,488.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts